EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z · by effect 18 graded findings

Liver and kidney

What human research has studied for liver and kidney measures, and injury reports, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.

Summary

How strong the evidence is

Show

Where liver and kidney sits on the supplement body map; colored by its strongest grade here.

Findings

Findings by ingredient

Liver and kidney: findings by ingredient and grade
IngredientGradeWhat was studied and found
Branched-chain amino acids (BCAAs)BHepatic encephalopathy in people with cirrhosis. A 2026 Cochrane review (18 RCTs, 934 adults; oral or intravenous) found BCAAs reduced hepatic encephalopathy (RR 0.79; low certainty); the effect on all-cause mortality was very uncertain. sources
PotassiumBKidney stones (potassium citrate). A 2015 Cochrane review (seven studies, 477 participants) found fewer new stones with potassium citrate; AHRQ judged supplement evidence insufficient. The proposed mechanism is citrate, not potassium itself. sources
AstragalusCKidney measures in membranous nephropathy (added to usual therapy). A 2023 review of 50 studies (3,423 participants) found greater improvement in some kidney indicators; authors cited low quality, small size and limited geographic location of the studies. sources
BenfotiamineCKidney damage markers in type 2 diabetic nephropathy. A 12-week RCT (82 patients, 900 mg/day, added to ACE inhibitors or ARBs) improved thiamine status but did not reduce urinary albumin or KIM-1 excretion. sources
CholineCNonalcoholic fatty liver disease. Observational and small studies link low choline intake to liver dysfunction or fibrosis; ODS states further research is needed. sources
CordycepsCKidney function in chronic kidney disease (C. sinensis preparations). Cochrane 2014: 22 studies (1,746 participants). With conventional treatment, cordyceps lowered serum creatinine (MD −60.76 µmol/L) and proteinuria in people not on dialysis; evidence was low quality. sources
CordycepsCKidney transplant recipients (C. sinensis preparations). Cochrane 2015: 5 studies (447 participants). Versus azathioprine, no difference in graft or patient survival, with possibly fewer acute rejections; all studies had unclear risk of bias. sources
Kutki (Picrorhiza)CAcute viral hepatitis (liver tests). In a small RCT (33 patients, HBsAg-negative acute viral hepatitis), root powder 375 mg three times daily for 2 weeks lowered bilirubin and liver enzymes faster than placebo (27.44 vs 75.9 days to bilirubin 2.5 mg%). sources
Milk thistleCAlcohol-related and hepatitis B or C liver disease. Cochrane (2007): 18 trials, 1,088 patients, mostly low quality; no significant effect on mortality, complications or histology; a liver-mortality signal vanished in high-quality trials. sources
RosemaryCFatty liver: liver enzymes, lipids and glucose. An 8-week double-blind RCT in 110 adults on a weight-loss diet found 4 g/day of rosemary leaf powder no better than placebo for liver enzymes, lipids or glucose. sources
Royal jellyCLiver enzymes and glycemic indices in adults. A 2023 meta-analysis of 10 RCTs found no significant overall effect on plasma liver enzymes or glycemic indices; fasting glucose fell in trials lasting 8 weeks or more and in non-healthy populations. sources
SAMe (S-adenosyl-L-methionine)CLiver disease. NCCIH states benefit in people is not established; for intrahepatic cholestasis of pregnancy, studies conflicted and data are insufficient, and research on other liver conditions is inconclusive. sources
SchisandraCLiver function measures. Small uncontrolled studies in liver transplant patients and chronic hepatitis suggested improved liver tests; MSK calls them inconclusive and notes schisandra can lower ALT and AST readings. sources
Sweet wormwoodCLiver enzymes in adults with mild-to-moderate non-alcoholic liver dysfunction. One placebo-controlled trial of a powdered water extract (SPB-201) reported larger AST and ALT decreases than placebo at 4 and 8 weeks, with no significant adverse events. sources
TocotrienolsCLiver markers in nonalcoholic fatty liver disease. A 24-week RCT (71 patients; delta-tocotrienol 300 mg twice daily) reduced fatty liver index, HOMA-IR, hs-CRP, ALT, AST and ultrasound steatosis grade versus placebo. sources
Turmeric (and curcumin)CNonalcoholic fatty liver disease measures. Initial research suggests oral turmeric or curcumin might improve some measures, but it is unclear which measures are consistently improved. sources
Kutki (Picrorhiza)DLiver protection in animals. In rats with galactosamine-induced liver injury, 200 mg/kg orally reduced liver lipid content and liver enzymes; this is an animal model, not a human outcome. sources
Milk thistleXHepatitis C and nonalcoholic steatohepatitis (NCCIH-funded trials). Two NCCIH-funded studies of the extract silymarin, one in hepatitis C and one in nonalcoholic steatohepatitis, did not show benefits. sources
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

All effect categories · All entries A–Z · Interactions

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.